PeptiDream Inc.

Tokyo Stock Exchange:4587.T

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🤖 Artificial Intelligence (AI)

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

Japan

Market Cap

USD 1.50 B

Share Price

USD 11.54

Avg Daily Volume

666,901

Change (1 day)

-4.23%

Change (1 year)

-15.64%

Change (YTD)

-31.53%

PeptiDream Inc. Gross Profit Margin for the year ending December 31, 2024: 73.92%

PeptiDream Inc. Gross Profit Margin is 73.92% for the year ending December 31, 2024, a 23.27% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

PeptiDream Inc. Gross Profit Margin for the year ending December 31, 2023 was 59.97%, a -11.10% change year over year.
PeptiDream Inc. Gross Profit Margin for the year ending December 31, 2022 was 67.46%, a -9.85% change year over year.
PeptiDream Inc. Gross Profit Margin for the year ending December 31, 2021 was 74.82%, a -8.31% change year over year.
PeptiDream Inc. Gross Profit Margin for the year ending December 31, 2020 was 81.61%, a 156.11% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Gross Profit Margin	EBIT Margin	EBITDA Margin	Net Income Margin

Tokyo Stock Exchange: 4587.T

PeptiDream Inc.

CEO	Dr. Patrick Crawford Reid Ph.D.
IPO Date	June 12, 2013
Location	Japan
Headquarters	3-25-23 Tonomachi
Employees	621
Sector	🏥 Health Care
Industries Pharmaceuticals 🤖 Artificial Intelligence (AI) 🧬 Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.